• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于主要组织相容性复合体I类呈递的蛋白酶体后抗原加工。

Post-proteasomal antigen processing for major histocompatibility complex class I presentation.

作者信息

Rock Kenneth L, York Ian A, Goldberg Alfred L

机构信息

Department of Pathology, University of Massachusetts Medical Center, Worcester, MA 01655, USA.

出版信息

Nat Immunol. 2004 Jul;5(7):670-7. doi: 10.1038/ni1089.

DOI:10.1038/ni1089
PMID:15224092
Abstract

Peptides presented by major histocompatibility complex class I molecules are derived mainly from cytosolic oligopeptides generated by proteasomes during the degradation of intracellular proteins. Proteasomal cleavages generate the final C terminus of these epitopes. Although proteasomes may produce mature epitopes that are eight to ten residues in length, they more often generate N-extended precursors that are too long to bind to major histocompatibility complex class I molecules. Such precursors are trimmed in the cytosol or in the endoplasmic reticulum by aminopeptidases that generate the N terminus of the presented epitope. Peptidases can also destroy epitopes by trimming peptides to below the size needed for presentation. In the cytosol, endopeptidases, especially thimet oligopeptidase, and aminopeptidases degrade many proteasomal products, thereby limiting the supply of many antigenic peptides. Thus, the extent of antigen presentation depends on the balance between several proteolytic processes that may generate or destroy epitopes.

摘要

主要组织相容性复合体I类分子呈递的肽主要源自蛋白酶体在细胞内蛋白质降解过程中产生的胞质寡肽。蛋白酶体切割产生这些表位的最终C末端。尽管蛋白酶体可能产生长度为8至10个残基的成熟表位,但它们更常产生N端延伸的前体,这些前体太长而无法与主要组织相容性复合体I类分子结合。此类前体在胞质溶胶或内质网中被氨肽酶修剪,从而产生呈递表位的N末端。肽酶也可通过将肽修剪至低于呈递所需的大小来破坏表位。在胞质溶胶中,内肽酶,尤其是硫醇寡肽酶和氨肽酶会降解许多蛋白酶体产物,从而限制了许多抗原肽的供应。因此,抗原呈递的程度取决于可能产生或破坏表位的几种蛋白水解过程之间的平衡。

相似文献

1
Post-proteasomal antigen processing for major histocompatibility complex class I presentation.用于主要组织相容性复合体I类呈递的蛋白酶体后抗原加工。
Nat Immunol. 2004 Jul;5(7):670-7. doi: 10.1038/ni1089.
2
Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides.不同的蛋白水解过程产生了与MHC I类结合肽的C端和N端。
J Immunol. 1999 Dec 1;163(11):5851-9.
3
Thimet oligopeptidase and the stability of MHC class I epitopes in macrophage cytosol.苏氨酸寡肽酶与巨噬细胞胞质溶胶中MHC I类表位的稳定性
Biochem Biophys Res Commun. 1999 Feb 24;255(3):596-601. doi: 10.1006/bbrc.1999.0251.
4
Thimet oligopeptidase (EC 3.4.24.15), a novel protein on the route of MHC class I antigen presentation.苏氨酸寡肽酶(EC 3.4.24.15),一种主要组织相容性复合体I类抗原呈递途径中的新蛋白。
Biochem Biophys Res Commun. 1999 Feb 24;255(3):591-5. doi: 10.1006/bbrc.1999.0250.
5
Complexity, contradictions, and conundrums: studying post-proteasomal proteolysis in HLA class I antigen presentation.复杂性、矛盾与难题:研究HLA I类抗原呈递中的蛋白酶体后蛋白水解作用
Immunol Rev. 2005 Oct;207:42-59. doi: 10.1111/j.0105-2896.2005.00313.x.
6
The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues.内质网氨肽酶ERAP1通过将表位修剪为8至9个残基来增强或限制抗原呈递。
Nat Immunol. 2002 Dec;3(12):1177-84. doi: 10.1038/ni860. Epub 2002 Nov 18.
7
MHC-encoded proteasome subunits LMP2 and LMP7 are not required for efficient antigen presentation.高效抗原呈递并不需要MHC编码的蛋白酶体亚基LMP2和LMP7。
J Immunol. 1994 Feb 1;152(3):1163-70.
8
Presentation assessment of minor histocompatibility antigens by predictive proteasomal cleavage analysis.通过预测性蛋白酶体裂解分析对次要组织相容性抗原进行呈现评估。
Ann Hematol. 2004 Feb;83(2):107-13. doi: 10.1007/s00277-003-0791-1. Epub 2003 Nov 26.
9
The proteasome activator 11 S REG (PA28) and class I antigen presentation.蛋白酶体激活剂11S REG(PA28)与I类抗原呈递。
Biochem J. 2000 Jan 1;345 Pt 1(Pt 1):1-15.
10
The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation.胞质内肽酶,硫醚寡肽酶,可破坏抗原肽并限制MHC I类抗原呈递的程度。
Immunity. 2003 Mar;18(3):429-40. doi: 10.1016/s1074-7613(03)00058-x.

引用本文的文献

1
Coordination of innate immune responses by connexins.连接蛋白对固有免疫反应的协调作用。
Front Immunol. 2025 May 22;16:1594015. doi: 10.3389/fimmu.2025.1594015. eCollection 2025.
2
Antitumour vaccination via the targeted proteolysis of antigens isolated from tumour lysates.通过对从肿瘤裂解物中分离的抗原进行靶向蛋白水解实现抗肿瘤疫苗接种。
Nat Biomed Eng. 2025 Feb;9(2):234-248. doi: 10.1038/s41551-024-01285-5. Epub 2024 Nov 28.
3
The Significant Role of PA28αβ in CD8 T Cell-Mediated Graft Rejection Contrasts with Its Negligible Impact on the Generation of MHC-I Ligands.
PA28αβ 在 CD8 T 细胞介导的移植物排斥反应中具有重要作用,而其对 MHC-I 配体的产生影响可以忽略不计。
Int J Mol Sci. 2024 May 22;25(11):5649. doi: 10.3390/ijms25115649.
4
Advances in pathogenesis and treatment of ocular involvement in Behcet's disease.贝赫切特病眼部受累的发病机制和治疗进展。
Front Immunol. 2023 Sep 29;14:1206959. doi: 10.3389/fimmu.2023.1206959. eCollection 2023.
5
Brain Hydrophobic Peptides Antagonists of Neurotoxic Amyloid β Peptide Monomers/Oligomers-Protein Interactions.脑疏水性肽对神经毒性淀粉样β肽单体/寡聚体与蛋白质相互作用的拮抗剂
Int J Mol Sci. 2023 Sep 8;24(18):13846. doi: 10.3390/ijms241813846.
6
Causal ALS genes impact the MHC class II antigen presentation pathway.因果性肌萎缩侧索硬化症基因影响 MHC Ⅱ类抗原呈递途径。
Proc Natl Acad Sci U S A. 2023 Sep 26;120(39):e2305756120. doi: 10.1073/pnas.2305756120. Epub 2023 Sep 18.
7
Interferons and Resistance Mechanisms in Tumors and Pathogen-Driven Diseases-Focus on the Major Histocompatibility Complex (MHC) Antigen Processing Pathway.干扰素与肿瘤及病原体驱动性疾病的耐药机制——以主要组织相容性复合体(MHC)抗原加工途径为重点。
Int J Mol Sci. 2023 Apr 4;24(7):6736. doi: 10.3390/ijms24076736.
8
EULAR study group on 'MHC-I-opathy': identifying disease-overarching mechanisms across disciplines and borders.EULAR 研究小组关于“MHC-I 病”:在学科和边界内识别疾病普遍存在的机制。
Ann Rheum Dis. 2023 Jul;82(7):887-896. doi: 10.1136/ard-2022-222852. Epub 2023 Mar 27.
9
Improving MHC class I antigen-processing predictions using representation learning and cleavage site-specific kernels.利用表示学习和切割位点特异性核函数提高 MHC Ⅰ类抗原加工预测。
Cell Rep Methods. 2022 Sep 19;2(9):100293. doi: 10.1016/j.crmeth.2022.100293.
10
Dual-responsive nanovaccine for cytosolic delivery of antigens to boost cellular immune responses and cancer immunotherapy.用于将抗原胞质递送以增强细胞免疫反应和癌症免疫治疗的双响应纳米疫苗。
Asian J Pharm Sci. 2022 Jul;17(4):583-595. doi: 10.1016/j.ajps.2022.05.004. Epub 2022 Jul 13.